U.S. regulators this week gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

The drugs' high prices, along with spotty insurance coverage, have left them out of reach for many Americans. Read more at ...

Tradipitant is a neurokinin-1 receptor antagonist licensed by Vanda from Eli Lilly and Company. ・The drug is also being ...

Hyderabad: Global pharma heavyweights Eli Lilly and Novo Nordisk are racing to lock in market leadership in India’s blooming ...

In a significant development for global health, U.S. regulators have approved an oral version of the Wegovy weight-loss drug, marking the first time this powerful treatment will be available in pill ...

Eli Lilly is the clear leader in the burgeoning weight loss market. Its lineup and pipeline put it well ahead of even its ...

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

The post Wegovy Wins First Weight-Loss Pill Approval appeared first on Self Employed.

THREE women from one family lost a combined weight of over 20st after turning to fat-busting jabs three years ago – and now they want to help others achieve their dream body. Debbie ...

Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become available in January, analysts say.

Major stock indexes ended higher for a fourth straight session Tuesday, with the S&P 500 setting a fresh closing record, ...